Efficacy of repeated high-dose
hepatitis B vaccine (80 μg) in
patients with chronic liver disease
A. Aziz, S. Aziz, D. S. Li, L.
Murphy, N. Leone, M. Kennedy, S.
Dhillon, D. H. Van Thiel
A rapid real-time PCR assay for
determination of hepatitis C virus
genotypes 1, 2 and 3a A. Moghaddam, N. Reinton, O.
Dalgard
Modulation of
the anti-inflammatory interleukin 10
and of proapoptotic IL-18 in
patients with chronic hepatitis C
treated with interferon alpha and
ribavirin E. Marín-Serrano, C. Rodríguez-Ramos,
F. Díaz, L. Martín-Herrera, J. A.
Girón-González
Comparison of
hepatitis C treatment patterns in
patients with and without
psychiatric and/or substance use
disorders†
S. Chainuvati, S. K. Khalid, S.
Kancir, M. Shea, J. Edwards, M.
Sernyak, S. Wongcharatrawee, G.
Garcia-Tsao
Black patients
with chronic hepatitis C have a
lower sustained viral response rate
than non-Blacks with genotype 1, but
the same with genotypes 2/3, and
this is not explained by more
frequent dose reductions of
interferon and ribavirin*
N. Bräu, E. J. Bini, S. Currie, H.
Shen, W. N. Schmidt, P. D. King, S.
B. Ho, R. C. Cheung, K.-Q. Hu, B. S.
Anand, F. R. Simon, A. Aytaman, D.
P. Johnson, J. A. Awad, J. Ahmad, C.
L. Mendenhall, M. C. Pedrosa, R. H.
Moseley, C. H. Hagedorn, B. Waters,
K.-M. Chang, T. R. Morgan, S. J.
Rossi, L. J. Jeffers, T. L. Wright,
The VA-HCV-001 Study Group
Switching to
adefovir monotherapy after emergence
of lamivudine-resistant mutations in
patients with liver cirrhosis
Y.-F. Liaw, C.-M. Lee, R.-N. Chien,
C.-T. Yeh
Safety and efficacy of lamivudine
in patients with severe acute or
fulminant hepatitis B, a multicenter
experience H. L. Tillmann, J. Hadem, L.
Leifeld, K. Zachou, A. Canbay, C.
Eisenbach, I. Graziadei, J. Encke,
H. Schmidt, W. Vogel, A. Schneider,
U. Spengler, G. Gerken, G. N.
Dalekos, H. Wedemeyer, M. P. Manns
Clinical pathways for patients
with newly diagnosed hepatitis C –
What actually happens
W. L. Irving, S. Smith, R. Cater, S.
Pugh, K. R. Neal, C. A. C. Coupland,
S. D. Ryder, B. J. Thomson, M.
Pringle, M. Bicknell, J. Hippisley-Cox
Is hepatitis C
virus a risk factor for thyroid
autoimmunity?
A. Floreani, C. Betterle, I. Carderi,
F. Presotto, B. Pedini, A. Moscon,
O. Di Andrea, M. Chiaramonte, Arsita-one
Research Group
A prospective
study of the evolution of lamivudine
resistance mutations in patients
with chronic hepatitis B treated
with lamivudine
F. Zoulim, T. Poynard, F. Degos, A.
Slama, A. El Hasnaoui, P. Blin, F.
Mercier, P. Deny, P. Landais, P.
Parvaz, C. Trepo, The Lamivir Study
Group
